Alx oncology announces results from phase 1b/2 trial of evorpacept in combination with zanidatamab will be presented at the san antonio breast cancer symposium (sabcs) 2024

Poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational cd47 blocker, in combination with zanidatamab, an investigational dual her2-targeted bispecific antibody, in patients with advanced breast cancers poster presentation will highlight new data from clinical trial evaluating evorpacept, a highly differentiated investigational cd47 blocker, in combination with zanidatamab, an investigational dual her2-targeted bispecific antibody, in patients with advanced breast cancers
ALXO Ratings Summary
ALXO Quant Ranking